Page 135 - Read Online

Page 12 of 12 An et al. Hepatoma Res 2023;9:43 https://dx.doi.org/10.20517/2394-5079.2023.60

61. Pomoni M, Malagari K, Moschouris H, et al. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead.
Hepatogastroenterology 2012;59:820-5. PubMed
62. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular
carcinoma: a systematic review of efficacy and safety data. Hepatology 2016;64:106-16. DOI PubMed
63. Clark TW. Complications of hepatic chemoembolization. Semin Intervent Radiol 2006;23:119-25. DOI PubMed PMC
64. Tu J, Jia Z, Ying X, et al. The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular
carcinoma. Medicine 2016;95:e5606. DOI PubMed PMC
65. Lamarca A, Palmer DH, Wasan HS, et al; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus
active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol
2021;22:690-701. DOI PubMed PMC
66. Gairing SJ, Thol F, Müller L, et al. The addition of transarterial chemoembolization to palliative chemotherapy extends survival in
intrahepatic cholangiocarcinoma. J Clin Med 2021;10:2732. DOI PubMed PMC
67. Martin RCG 2nd, Simo KA, Hansen P, et al. Drug-eluting bead, irinotecan therapy of unresectable intrahepatic cholangiocarcinoma
(DELTIC) with concomitant systemic gemcitabine and cisplatin. Ann Surg Oncol 2022;29:5462-73. DOI
68. Cucchetti A, Cappelli A, Mosconi C, et al. Improving patient selection for selective internal radiation therapy of intra-hepatic
cholangiocarcinoma: a meta-regression study. Liver Int 2017;37:1056-64. DOI PubMed
69. Edeline J, Du FL, Rayar M, et al. Glass Microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment
of intrahepatic cholangiocarcinoma. Clin Nucl Med 2015;40:851-5. DOI
70. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic
cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020;6:51-9. DOI PubMed PMC
71. SIRT followed by CIS-GEM chemotherapy versus CIS-GEM chemotherapy alone as 1st line treatment of patients with unresectable
intrahepatic cholangiocarcinoma (SIRCCA). Available from: https://clinicaltrials.gov/ct2/show/study/NCT02807181 [Last accessed
on 27 Sep 2023].
72. Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol
2020;12:693-708. DOI PubMed PMC
73. Holster JJ, El Hassnaoui M, Franssen S, et al. Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic
cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 2022;29:5528-38. DOI PubMed PMC
74. Franssen S, Soares KC, Jolissaint JS, et al. Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with
multifocal intrahepatic cholangiocarcinoma. JAMA Surg 2022;157:590-6. DOI PubMed PMC
75. Oh D, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022:1.
DOI
76. Yang XG, Sun YY, Li DS, Xu GH, Huang XQ. Efficacy and safety of drug-eluting beads transarterial chemoembolization combining
immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis. Front Immunol
2022;13:940009. DOI PubMed PMC